Unknown PHASE2 INTERVENTIONAL 1-arm NCT02733380

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

The Efficacy and Safety of Chidamide Combined With VDDT Regimen（Vinorelbine，Liposomal Doxorubicin，Dexamethasone and Thalidomide） in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma

Sponsor: Henan Cancer Hospital

Conditions Diffuse Large B-cell Lymphoma

Interventions Chidamide Dexamethasone Liposomal Doxorubicin or mitoxantrone Thalidomide Vinorelbine

Updated 9 times since 2017 Last updated: Mar 31, 2020 Started: May 31, 2016 Primary completion: May 31, 2020 Completion: May 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02733380, this PHASE2 trial focuses on Diffuse Large B-cell Lymphoma and remains ongoing. Sponsored by Henan Cancer Hospital, it has been updated 9 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

May 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Sep 2018 — May 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Cancer Hospital

Data source: Henan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China